The generics company $TEVA with a pipeline, Ajovy’s OK last fall was one of the rare R&D bright spots at the company, which has been undergoing a wrenching restructuring in the last 18 months. But researchers for the company said on Tuesday that they are scrapping a Phase III trial for episodic cluster headaches after the drug (fremanezumab) failed to clear a futility test.

The setback will cost Teva some of the badly needed upside on this drug, which the Bloomberg consensus set at about $500 million for 2022 sales — Leerink projected $629 million in 2023 — as the drugs in the class divvy up a multibillion-dollar market. This drug was the second CGRP therapy to get past regulators, following Aimovig from Novartis $NVS and Amgen $AMGN, now the subject of a legal battle over the future of their alliance.

Teva’s loss here could be its rivals’ gain. Eli Lilly recently snagged a priority review for its CGRP contender Emgality as a treatment for cluster headaches, offering some mixed data from that program.

Alder $ALDR, the last of the CGRP contenders, announced just hours ago that their pitch has been accepted by the FDA. And the little company could disrupt a migraine market where the price is lined up at $6,900 a year.

Sign in to Endpoints News

Request a magic link

Enter your email below to get a Magic link which lets you sign in quickly without using a password.Please note the Magic link is one-time use only and valid for only 24 hours.
Email:

← Go back

Set a new password

We will send you a link, with which you will be able to set a new password.Please note this link is for one-time use only and valid for only 24 hours.
Email:

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 51,200+ biopharma executives who read Endpoints News every day.